国产av不卡一区二区_欧美xxxx做受欧美_成年人看的毛片_亚洲第一天堂在线观看_亚洲午夜精品久久久中文影院av_8x8ⅹ国产精品一区二区二区_久久精品国产sm调教网站演员_亚洲av综合色区无码一二三区_成人免费激情视频_国产九九九视频

  Home>News Center>World
         
 

Pfizer: Celebrex raises heart attack risk
(Agencies)
Updated: 2004-12-18 14:48

A bottle of Vioxx, right, is photographed next to a bottle Pfizer's Celebrex at a pharmacy in New York Sept. 30, 2004. Pfizer Inc. said Friday, Dec. 17, 2004, it has found an increased risk of heart problems with patients taking its painkiller Celebrex, a drug that is in the same class as the Vioxx, which was pulled from the market in September because of safety concerns. (AP
A bottle of Vioxx, right, is photographed next to a bottle Pfizer's Celebrex at a pharmacy in New York Sept. 30, 2004. Pfizer Inc. said Friday, Dec. 17, 2004, it has found an increased risk of heart problems with patients taking its painkiller Celebrex, a drug that is in the same class as the Vioxx, which was pulled from the market in September because of safety concerns. [AP]
Pfizer Inc. said it found an increased risk of heart attacks and strokes for patients taking high dosages of its top-selling arthritis painkiller Celebrex, the same problem that led to the withdrawal of its one-time competitor Vioxx.

The company said it has no plans to remove Celebrex from the market, but the disclosure on Friday sent Pfizer's shares tumbling because of fears that it could cripple sales of what had been the most-prescribed drug for treating arthritis.

Acting FDA Commissioner Lester Crawford said the government is advising physicians to consider prescribing drugs other than Celebrex to their patients.

"We're leaving open all regulatory decisions as we move forward. But we do not have a decision on the fate of the product," said Crawford, during a press briefing. "We do have great concern about this product (Celebrex) and the class of products."

But doctors have already been inundated with phone calls from worried patients and say they will curtail writing prescriptions for the drug. Shares of Pfizer, a member of the Dow index and the world's largest pharmaceutical maker, plunged $3.23, or 11.15 percent, to $25.75 in late afternoon trading on the New York Stock Exchange. The decline wiped out almost $25 billion of Pfizer's market value.

The drug industry has already been under fire for numerous high profile debacles: Merck & Co.'s withdrawal of Vioxx, the failure of Chiron Corp. to deliver half the country's flu vaccines, and disclosures that drug companies had stifled negative clinical trial data from studies examining anti-depressant use in children.

Both Celebrex and Vioxx are a type of drug called cox-2 inhibitors. Vioxx was pulled from the market in September because it doubled patients' risk of heart attack and strokes.

National Institutes of Health director Dr. Elias Zerhouni said that he ordered a full review of the more than 40 agency-supported studies involving cox-2 inhibitors.

Pfizer Global Research and Development signage is seen outside an entrance to its facility January 22, 2004 in Skokie, Illinois. Three US doctors have called for physicians worldwide to stop prescribing the pain-killing drug Bextra which is made by Pfizer, whose Celebrex drug was the subject of a separate warning.(AFP
Pfizer Global Research and Development signage is seen outside an entrance to its facility January 22, 2004 in Skokie, Illinois. Three US doctors have called for physicians worldwide to stop prescribing the pain-killing drug Bextra which is made by Pfizer, whose Celebrex drug was the subject of a separate warning.[AFP]
News of the increased heart risk for patients using Celebrex came in one of two long-term cancer prevention trials.

The National Cancer Institute, which was conducting the study for Pfizer, said patients in the clinical trial taking 800 milligrams of Celebrex had a 3.4 times greater risk of cardiovascular events compared to a placebo. For patients in the trial taking 400 milligrams of Celebrex the risk was 2.5 times greater. The average duration of treatment in the trial was 33 months.

In the 2,000 patient study, 15 individuals taking 400 mgs, 20 patients taking 800 mgs and 6 patients on placebo suffered either a cardiac-related death, heart attack or stroke.

The study was intended to show whether Celebrex could prevent precancerous growths called polyps in patients that had already had at least one such growth.

A separate cancer study done by Pfizer found no increased heart risk with patients taking 400mg of Celebrex per day.

Pfizer chairman and chief executive Hank McKinnell, who takes Celebrex, told CNN's Paula Zahn that plans to continue using the drug.

Dr. Joseph Feczko, president of worldwide development for Pfizer, noted that the results in the trial finding increased risk of heart attacks were not consistent with either the other cancer prevention trial or with a "large body of data" that the company had collected.

Feczko said in an interview later in the day that sales of Celebrex will continue because "it has not shown in totality that it increases the risk of heart attacks." He said Pfizer still hadn't seen the data from the NCI study so he couldn't speculate on how the two trials could have such different outcomes. He added that the company was still planning to go ahead with a previously announced study to see if Celebrex could actually help patients at high risk of heart attacks.

Finding patients to participate in such a study will be challenge because doctors are now saying patients at high risk of heart attacks should avoid taking Celebrex.

Dr. Garret A. FitzGerald, who has been critical of cox-2 inhibitors, said he doesn't believe Pfizer should take Celebrex off market but has to work hard to find the appropriate patient population for the drug. Cox-2s were developed to be gentler on the stomach than older pain relievers called nonsteroidal anti-inflammatory drugs, such as naproxen, that are associated with gastrointestinal problems. But unlike Vioxx, Celebrex was never statistically proven to decrease the risk of ulcers. It also doesn't reduce pain better than older drugs.

"The challenge for Pfizer now is to show why this drug should be chosen," said FitzGerald, a cardiologist at the University of Pennsylvania.

FitzGerald said Pfizer's huge marketing push behind the drug accounted for its dramatic use. Last year, Pfizer spent $87.6 million to advertise Celebrex, according to TNS Media Intelligence/CMR. It recently launched a new campaign for the drug and placed full-page ads in newspapers touting Celebrex's safety in the wake of the Vioxx recall.

Those safety claims may cause problems for the Pfizer. Citing recent company statements, including a Nov. 4 press release touting the drug's safety, U.S. Rep. Joe Barton (news, bio, voting record), R-Texas, and U.S. Rep. John Dingell, D-Mich., asked Pfizer on Friday for documents regarding Celebrex and Bextra, the company's other Cox-2 inhibitor. They want to know what information Pfizer had about the NCI study when it made the safety statements.

Additionally, they want to understand how the data safety monitor board that reviewed the ongoing trial in September and October could have determined to proceed with the study only to have it stopped two months later.

Meanwhile, Consumer Group Public Citizen called on the FDA to ban both Celebrex and Bextra.

FitzGerald said he believed the news has implications for cox-2 inhibitors such as those under development at Merck and Novartis.

"I think the trial concludes the controversy about whether there is a class effect of these drugs. Now there is clear evidence of it," said FitzGerald. "You would need to believe the earth is flat if you thought this was just a coincidence."

For the first nine months of the year, worldwide sales of Celebrex more than doubled from a year earlier to $2.3 billion, accounting for 6 percent of Pfizer's total sales of $37.6 billion during that period.

Barbara Ryan, a managing director at Deutsche Bank said she expects Celebrex's sales to fall by 50 percent next year and has dropped her Pfizer 2005 earnings estimate to $2.10 a share from $2.35 a share.

"In this environment people are hysterical," said Ryan, who said all the headlines would scare people even though the drug's problem manifested itself at high doses.

Moody's Investors Service revised its outlook on Pfizer to negative from stable because it believes Celebrex use may decline as the controversy about the class increases. Moreover, it said the likelihood that the drug could be pulled from the market may have risen and Pfizer's litigation may increase.

Moody's points out that this is happening when Pfizer is facing high exposure to patent expirations, with 30 percent to 35 percent of its revenues coming off Patent through 2007. The combination means Pfizer may not be able to maintain its triple A rating, Moody's said.

Dr. Marie Griffin, an epidemiologist and drug safety expert at Vanderbilt University, said concerns may only apply to patients taking Celebrex at high doses.

She noted that the halted study was testing a 400 to 800 milligram dose. The highest recommended dose for Celebrex to treat rheumatoid patients is 400 milligrams a day while the dose for osteoarthritis patients is 200 milligrams a day.

Still, some doctors are concerned about the drug at lower doses because different patients metabolize drugs at different rates.

"You can't say as a result of this study that doses under 400 milligrams are absolutely safe," said Dr. Eric Matteson, a professor of medicine in the division of rheumatology at the Mayo Clinic in Rochester, Minn.

Matteson said his office has been besieged with calls and that he plans to review his patients' records and take some of them off the drug. Some have specifically asked to be given something else.

The withdrawal of Vioxx has been a financial and public relations disaster for Merck. Its legal liabilities are estimated at up to $18 billion, and its shares have dropped by nearly one-third since the recall announcement in late September.

Vioxx had been a blockbuster drug for Merck, its No. 2 earner with annual global sales of $2.5 billion, amounting to 11 percent of the company's $22.49 billion in revenue last year.

Earlier this month, the Food and Drug Administration said it was adding a warning to the labels of another Pfizer drug, Bextra, noting a risk of potential heart problems associated with the use of Bextra in people who have recently had heart bypass surgery. Bextra is also a cox-2 inhibitor type of drug.

Griffin and two other Vanderbilt epidemiologists also raised fresh concerns about Bextra, in a letter to be published Thursday in the New England Journal of Medicine. Doctors should not prescribe the drug "except in extraordinary circumstances," they recommend.

Last month, in testimony before Congress an FDA official said that Bextra was one of five drugs whose sales should be halted or curtailed because it is unsafe.



 
  Today's Top News     Top World News
 

China prepares to enact law against secession

 

   
 

EU hints to lift China arms ban in June

 

   
 

GM charges Chery for alleged mini car piracy

 

   
 

More cash allotted to cut poverty

 

   
 

Unemployment rate lower than expected

 

   
 

Info chief promises media better service

 

   
  Japan delays sanctioning North Korea
   
  Saddam's defense minister faces hearing
   
  Japan, US sign missile defense agreement
   
  EU requirements dismay Turkish officials
   
  AP: Yushchenko poisoned by worst dioxin
   
  Sharon offers state to Palestinians
   
 
  Go to Another Section  
 
 
  Story Tools  
   
  News Talk  
  Are the Republicans exploiting the memory of 9/11?  
Advertisement
         
国产成人手机高清在线观看网站| 亚洲精品在线免费观看视频| 亚洲成人av在线电影| 国产精品另类一区| 91美女精品福利| 国产v综合v亚洲欧| 久久99精品网久久| 视频一区二区国产| 99热精品在线| 极品裸体白嫩激情啪啪国产精品| 色综合天天综合网中文字幕| 亚洲性视频大全| 欧美电影在线观看免费| 91成人福利| av日韩一区| 欧美精品资源| 欧美日韩免费观看视频| 中文字幕一区久| www视频在线观看| 福利写真视频网站在线| 亚洲精品白浆| 污片在线免费观看| 2024短剧网剧在线观看| 伊人在我在线看导航| a在线免费观看| 成人免费看片| 性欧美高清come| 性网站在线观看| 日韩精品卡一| 免费在线看污片| caoprom在线| 爱啪啪综合导航| 黄色在线观看www| 99亚偷拍自图区亚洲| 日本欧美不卡| 成人片免费看| 欧美片第一页| 成人网ww555视频免费看| 成人免费在线观看视频| 国语自产精品视频在线看抢先版结局| 国产精品亲子伦av一区二区三区| 亚洲一区二区三区久久久| 国内精品视频| 波多野结衣欧美| 免费萌白酱国产一区二区三区| 精品国产一区二区三区不卡蜜臂 | 国产女人18水真多18精品一级做| 国产欧美一区二区精品久导航 | 亚洲国产精久久久久久久| 亚洲精品国精品久久99热| 精品视频—区二区三区免费| 正在播放欧美一区| 大胆欧美人体视频| 97av视频在线| 性欧美video视频另类| 欧美高清性xxxxxxx| 91caopron| 天天操天天插| 宅男深夜国产| 国产乱视频在线观看| 欧美性videos| 天堂中文最新版在线中文| 国产极品嫩模在线观看91精品| 日韩成人视屏| 国产一区二区三区四区五区传媒| 欧美日韩在线网站| 欧美私人啪啪vps| 久久精品二区三区| 国产成人精品午夜视频免费| 久久影院午夜论| 亚洲天天做日日做天天谢日日欢| 欧美午夜女人视频在线| 555www色欧美视频| 亚洲欧美一区二区激情| 色综合天天狠天天透天天伊人| 中文字幕中文字幕| 免费看成年人视频| 超碰在线电影| 午夜在线免费观看视频| 国产直播在线| 激情综合婷婷| 日韩av免费大片| 影音国产精品| 精品一区二区精品| 久久免费电影网| 洋洋成人永久网站入口| 欧美色视频在线观看| 亚洲精品美女在线观看播放| 欧美成人久久久| 亚洲精品xxxxx| sese在线播放| 四虎在线观看| 92久久精品| 色播一区二区| 91成人免费| 久久av资源网| 久久精品一级爱片| 精品高清美女精品国产区| 日韩欧美一级特黄在线播放| 色婷婷久久av| 伦理天堂电影| av日韩在线免费| 日本精品在线| 国产福利亚洲| 日韩精品影视| 蜜臀va亚洲va欧美va天堂 | 久久久久久久久久久人体| 国产亚洲精品久久久久久青梅| 人人澡人一摸人人添| 国产美女视频一区二区三区| 东京一区二区| 久久不见久久见国语| 亚洲一卡久久| 2欧美一区二区三区在线观看视频| 亚洲1区2区3区视频| 亚洲第一福利在线观看| 欧美二区乱c黑人| 蜜桃传媒入口| 国产中文字幕在线看| 国产精品迅雷| 伊人久久大香线蕉无限次| 久久久久国产精品一区二区| 成人av电影免费在线播放| 亚洲第一福利视频在线| 亚洲国产欧美自拍| 456亚洲影院| 男女无套免费网站| yellow91字幕网在线| 日韩有吗在线观看| 狠久久av成人天堂| 97精品国产露脸对白| 色综合一个色综合亚洲| 国产亚洲视频在线观看| 日本欧美黄色| 在线中文av| 成人影院大全| 99热国内精品永久免费观看| 国产福利不卡视频| 天天色 色综合| 亚洲视频国产视频| 国精品日韩欧美一区二区三区| 一本大道香蕉久在线播放29| free欧美| 欧美成人有码| 91亚洲国产成人精品一区二三 | 一二三区在线观看| 69堂精品视频在线播放| 亚洲色图网站| 91视频在线观看免费| 欧美综合视频在线观看| 久久福利网址导航| av小次郎收藏| 欧美1234区| 女人丝袜激情亚洲| 国产真实乱偷精品视频免| 午夜亚洲福利老司机| 亚洲三级av在线| 国产二级c片l毛片| 最新97超碰在线| 一区二区三区视频免费视频观看网站| 母乳一区在线观看| 亚洲色图视频网| 日韩精品亚洲元码| 国产精品午夜剧场| av亚洲在线| 欧美巨大xxxx| 激情文学综合丁香| 色综合色狠狠天天综合色| 久久99青青精品免费观看| 黄色成人免费观看| 亚洲人体影院| 欧美a级一区| 国产欧美日韩在线观看| 337p日本欧洲亚洲大胆色噜噜| 日韩8x8x| 888av在线| 伦理一区二区| 国产精品自拍一区| 欧美日韩一级黄| 91精品国产成人| 最新精品视频在线| 日韩欧美另类中文字幕| 青青草成人在线观看| 偷拍与自拍一区| 欧美精品一区三区| 超碰在线图片| 国产日韩欧美中文在线| 日韩中文字幕av电影| 精品国产老师黑色丝袜高跟鞋| 欧美另类在线播放| 最近2018中文字幕免费在线视频| 91精品麻豆| 日韩中文字幕91| 欧美性生交xxxxxdddd| 欧美精品videossex88| 中文字幕在线中文字幕二区| 亚洲一区二区免费在线观看| 久久国产生活片100| 欧美自拍丝袜亚洲| 中文av资源| 男人在线资源站| 日韩欧美1区| 国产日产欧美一区| 国产一区二区黄| 免费免费啪视频在线观看| 亚洲国产伊人| 极品少妇一区二区三区精品视频| 欧美性猛交xxxx乱大交退制版| 亚洲午夜网未来影院| 精品视频一二三| 神马久久av| 久久婷婷久久一区二区三区| 日韩精品免费观看| 久草在线资源网站| 伊人亚洲精品| 国产精品亚洲一区二区三区妖精 | 91精品久久久久久久91蜜桃| 国产麻豆综合视频在线观看| 国精一区二区三区| 日韩一级免费| 91成人免费电影| 欧美日韩看片| 久草在线新免费首页资源站| 亚洲另类黄色| 色哦色哦哦色天天综合| 青青草原国产在线观看| 免费看电影在线| 国产一区二区你懂的| 色妞www精品视频| 久久国产精品久久久久久小说| 波多野结衣精品| 国产欧美日韩综合一区在线播放 | 国产91在线精品| 国产一区二区导航在线播放| 亚洲黄在线观看| 成人免费淫片95视频观看网站| 国产成年精品| 成人黄色小视频在线观看| 亚洲欧美日韩国产精品| 色av一区二区三区| 欧美日韩一区二区三区四区不卡 | 欧美视频在线观看免费网址| 影音先锋中文字幕在线| gogo久久| 毛片一区二区三区| 日韩一区国产二区欧美三区| av影音资源| 波多野结衣一区二区三区免费视频| 91色|porny| 日韩中文视频免费在线观看| 男男电影完整版在线观看| 香蕉视频国产精品| 婷婷开心久久网| 欧美激情一级二级三级在线视频| 日韩av一卡| 黄色精品一二区| 亚洲精品久久久久| 少妇免费视频| 国产尤物视频| 自己做鸭怎么接单寻找客源| 日本成人三级电影| 国产一区二区三区四区五区入口 | 中文字幕在线高清| 国产在线精品一区二区不卡了| 亚洲精品aⅴ中文字幕乱码| 神马午夜dy888| 精品国产一区二区三区| 亚洲一区免费在线观看| 欧美一级淫片a免费视频| 老司机成人影院| 粉嫩一区二区三区在线看| 宅男66日本亚洲欧美视频| 国产高清视频免费最新在线| 亚洲婷婷免费| 制服丝袜亚洲网站| 18av.com视频| 欧美日韩老妇| 精品国产91久久久久久| 天堂网在线观看| 日韩欧美久久| 中文字幕亚洲一区二区av在线 | 亚洲精品国产首次亮相| 色婷婷综合久久久久中文一区二区| 软萌小仙自慰喷白浆| 精品国产一级| 国产精品久久久久久妇女6080| 男人天堂网页| 成人久久网站| 久久久久久久久99精品| 午夜精品久久久久久久99热 | 2022成人影院| 成人黄色大片在线观看 | 国产伦精品一区二区三区视频小说| 成人在线免费av| 久久人人97超碰com| 91禁国产网站| 色老太综合网| 久久无码av三级| 欧美一级淫片丝袜脚交| 免费在线观看一区| 久久精品一二三| 成人久久在线| 中文成人在线| 国产精品国产三级国产aⅴ无密码| 丝袜理论片在线观看| 成人豆花视频| 亚洲人成网站在线| 99re这里有精品| 卡通动漫国产精品| 欧美日韩精品在线播放| 日日摸日日添日日躁av| 国产一区二区电影在线观看| 在线一区二区三区| 韩国版免费三体| 女主播福利一区| 欧美哺乳videos| 国产香蕉在线| 免费观看成人鲁鲁鲁鲁鲁视频| 视频一区视频二区国产精品| 欧洲黄色一区| 99视频在线精品| √天堂中文在线| av在线成人| 亚洲一区二区三区四区在线| 人人影院免费大片| 欧洲grand老妇人| 欧美日韩第一区日日骚| 色视频在线播放| 久久av一区| 中文字幕亚洲欧美| 97超碰在线免费| 国产亚洲一区二区三区| 国产丝袜自拍| 妖精一区二区三区精品视频| 色欧美乱欧美15图片| av超碰在线| 视频一区二区三区在线| 精品国产一区二区三区久久狼5月| 91久久精品一区二区三区| 原千岁中文字幕| 亚洲免费在线| 日韩中文字幕网站| 刘亦菲一区二区三区免费看| 最新热久久免费视频| 美女极度色诱视频www免费观看| 国产精品久久久久无码av| 精品福利一二区| 高潮毛片在线观看| www.久久精品| 欧美xxxxbbbb| 国产精品最新| 日韩欧美国产一区在线观看| porn视频在线观看| 成人精品鲁一区一区二区| 最新中文乱码字字幕在线| 国产精品jk白丝蜜臀av小说 | 欧美日产国产精品| 你懂的视频在线免费| 国产乱码精品1区2区3区| 中文字幕在线观看av| 亚洲色图美女| 欧美成人欧美edvon| 菠萝蜜视频国产在线播放| 91麻豆免费看| 超碰在线91| 欧美精品黄色| 最近2019中文字幕第三页视频 | 欧美丰满少妇xxxbbb| yw在线观看| av在线不卡观看免费观看| 精品一成人岛国片在线观看| 97精品一区| 亚洲日本中文字幕| 色综合一本到久久亚洲91| 亚洲一级电影视频| 最近最好的中文字幕2019免费| 日韩电影在线免费观看| 国模叶桐国产精品一区| 国产成人一二片| 欧美一区二区在线播放| 久cao在线| 欧美国产日本视频| av先锋下载| 水蜜桃久久夜色精品一区的特点| 久久久欧美一区二区| 麻豆成人入口| 精品久久久久久久一区二区蜜臀| √8天堂资源地址中文在线| 亚洲欧美日韩国产综合| 女人体1963| 国产一区二区三区蝌蚪| 欧美午夜性春猛xxxx| 91综合久久| 中文字幕国内精品| 韩国三级成人在线| 欧美一级片在线看| 123区在线| 亚洲国产成人av| 男人天堂综合| 久久久久久一二三区|